Essential Thrombocythemia (ET) Market

Aug 04, 2020

10 likes | 24 Views

The total prevalent population of Essential Thrombocythemia (ET) in 2017 was 232,688 in the seven major markets. With 142,635 cases in 2017, the United States registered the highest prevalent population of Essential Thrombocythemia among the 7MM. Out of all the cases in the United States (in 2017), it is being observed that the age-group of 60-80 years accounted for the highest cases of Essential Thrombocythemia. The market size of Essential Thrombocythemia (ET) was found to be USD 616.05 Million in 2017, which is expected to increase during the forecast period 2017-2030. Rich emerging pipeline, updated diagnostic criteria, reach of bone marrow biopsy, and research & development are some of the key factors expected to drive the Essential Thrombocythemia (ET) market forward in the coming years. The key players in the Essential Thrombocythemia Market includes PharmaEssentia, Eli Lilly and Company, Novartis, Geron Corporation, Italfarmaco, Imago BioSciences, Galena Pharma, and many others. For more details visit: https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights

DelveInsight

Download Presentation

Essential Thrombocythemia (ET) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D